Adlai Nortye Ltd. announced that it will present encouraging preliminary data of AN0025 in combination with definitive chemoradiotherapy (dCRT) in unresectable locally advanced or locally recurrent esophageal cancer (EC) at the upcoming American Society of Cancer Oncology (ASCO) Annual Meeting to be held in Chicago from May 31 to June 4, 2024. AN0025 is a selective EP4 inhibitor that demonstrates antitumor activity by modulating the function of macrophages and immunosuppressive myeloid cells in tumor microenvironment. The combination of AN0025 with CRT as neoadjuvant therapy has shown synergistic antitumor efficacy in locally advanced rectal cancer in a prior clinical trial (NCT03152370).

The AN0025S0104 study is a single-arm, open-label, multicenter, Phase Ib study comprising a dose escalation phase followed by an expansion phase, aimed at evaluating the safety, tolerability, and feasibility of AN0025 plus dCRT for unresectable locally advanced and locally recurrent EC or esophagogastric conjunction cancer. Details regarding the Adlai Nortye abstract at ASCO 2024 are as follows: Abstract title: AN0025 in combination with Definitive chemoradiotherapy (d CRT) in unresectable local advanced or locally recurrent esophagal cancer (EC): a single-arm, open thelabel, multicenter, Phase I study (AN0025S0104). First Author: Nan Bi, Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College.